Pacira Pharmaceuticals (PCRX) PT Raised to $48 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Pacira Pharmaceuticals (PCRX) PT Raised to $37 at Leerink Partners
April 10, 2018 6:16 AM EDTLeerink Partners raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $37.00 (from $34.00) while maintaining a Market Perform rating.
... MorePacira Pharmaceuticals (PCRX) PT Raised to $80 at Wedbush After EXPAREL Nerve Block sNDA Approved
April 9, 2018 3:54 PM EDTWedbush raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $80.00 (from $72.00) while maintaining a Outperform rating after the FDA approved a new indication for EXPAREL (bupivacaine liposome injectable suspension) for use as an interscalene brachial plexus nerve block to relieve pain associated with... More
Pacira Pharmaceuticals (PCRX) PT Raised to $34 at BMO Capital
April 9, 2018 6:32 AM EDTBMO Capital raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $34.00 (from $31.00) while maintaining a Market Perform rating after the company received approval for an upper extremity nerve block indication for Exparel on the PDUFA.
Analyst Gary Nachman commented, "This was... More
Pacira Pharmaceuticals (PCRX) PT Raised to $48 at Seaport Global Securities
April 9, 2018 1:14 AM EDTSeaport Global Securities raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $48.00 (from $42.00) while maintaining a Buy rating.
... MorePacira Pharmaceuticals (PCRX) PT Raised to $34 at Canaccord Genuity
April 9, 2018 1:10 AM EDTCanaccord Genuity raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $34.00 (from $32.00) while maintaining a Hold rating.
... More